Share ownership Vaxcyte, Inc.

PCVX

US92243G1085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 14/09/2024 am IST			5-day change	1st Jan Change
116.00 ^USD	+1.64%		+3.96%	+84.71%

10/09	Analyst recommendations: Apple, Oracle, Progressive, Dollar Tree...
10/09	Mizuho Boosts Price Target on Vaxcyte to $163 From $113, Maintains Outperform Rating	MT

Share class: Vaxcyte, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	132,857,546	118,283,297 ( 89.03 %)	0	89.03 %

Major shareholders: Vaxcyte, Inc.

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 14.49 %	16,167,340	14.49 %	1 306 M $
Vanguard Fiduciary Trust Co. 8.778 %	9,796,995	8.778 %	791 M $
BlackRock Advisors LLC 8.235 %	9,191,343	8.235 %	742 M $
Janus Henderson Investors US LLC 7.946 %	8,868,907	7.946 %	716 M $
RA Capital Management LP 7.350 %	8,203,754	7.350 %	663 M $
Wellington Trust Co., NA 4.115 %	4,593,066	4.115 %	371 M $
Capital Research & Management Co. (Global Investors) 3.704 %	4,133,544	3.704 %	334 M $
T. Rowe Price Investment Management, Inc. 3.604 %	4,022,589	3.604 %	325 M $
State Street Corp. 3.017 %	3,367,147	3.017 %	272 M $
T. Rowe Price International Ltd. 2.843 %	3,173,167	2.843 %	256 M $
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	96.46%
Other	10.10%
State Street Corp.	3.02%
Individuals	1.02%
SEI Investments Co.	0.18%
Schweizerische Nationalbank	0.16%
Manulife Financial Corp.	0.12%
Corebridge Financial, Inc.	0.05%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	100.31%
United Kingdom	6.41%
Individuals	1.02%
Norway	0.90%
Denmark	0.85%
Switzerland	0.73%
Canada	0.61%
Germany	0.08%
Ireland	0.04%
Austria	0.03%
Japan	0.03%
China	0.02%
Sweden	0.02%
Singapore	0.02%
South Korea	0.01%
Hong Kong	0.01%
Taiwan	0.01%
Luxembourg	0.01%

Based on 1000 largest holdings

Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

Employees

254

Sector

Biotechnology & Medical Research

Calendar

18/09/2024 - Cantor Global Healthcare Conference

More about the company

Share ownership Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Biotechnology & Medical Research

Share class: Vaxcyte, Inc.

Major shareholders: Vaxcyte, Inc.

Breakdown by shareholder type

Geographical origin of shareholders

Company Profile